{"id":"260256215861-19","name":"Otsuka Novel Products GmbH","registrationDate":"2015-02-02T12:32:25.466+01:00","category":2,"subCategory":3,"legal":"GmbH","web":"http://otsuka-onpg.com","country":"Germany","headAddress":"Erika-Mann-Str. 21","headCity":"München","headPostCode":"80636","headPhone":"(49)2 06 02 05 00","boss":"Robert Dornheim","bossTitle":"Mr","bossPosition":"Geschäftsführer","membersCount":4,"membersFTE":"1.0","membership":"","memberOrga":"","goal":"Otsuka Novel Products GmbH (ONPG), based in Munich/Germany, was founded by the global Otsuka-group in 2010. The main focus of the company is the therapeutic area of tuberculosis. ONPG is Marketing Authorization Holder in Europe for Deltyba, a medicine for the treatment of multidrug-resistant tuberculosis (MDR-TB). Deltyba was approved for use in the EU in April 2014.","acronym":"ONPG","interests":"Humanitarian aid and civil protection, Public Health, Research and innovation","euInitiatives":"Rapid and equitable access to pharmaceuticals worldwide in the area of tuberculosis.","lastUp":"2019-12-06T16:04:21.197+01:00","customers":"","costAbsolu":"","costRange":"0-9999","turnoverAbsolu":0,"turnoverRange":""}